^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

RNA synthesis inhibitor

1d
Development and validation of a novel prognostic and for osteosarcoma patients utilizing multiple organelle related genes. (PubMed, Discov Oncol)
Drug sensitivity analysis revealed differential responses to 4 drugs between the risk groups, with the 3 ORGs (ACSS2, CLTCL1 and PLD3) showing positive correlations with 2 drugs (BI_2536, Dactinomycin). Additionally, functional experiments confirmed the role of ACSS2 in OS cell behavior. This novel ORG signature not only provides a valuable tool for patient stratification but also offers insights into the biological processes driving OS progression and potential therapeutic targets.
Journal
|
ACSS2 (Acyl-CoA Synthetase Short Chain Family Member 2)
|
dactinomycin • BI2536
2d
Tumor-Derived Exosomal piR-hsa-28212 Promotes Lymphatic Metastasis in Breast Cancer. (PubMed, Cancer Sci)
The stability of TBX1 mRNA was analyzed by actinomycin D assay...Collectively, these findings reveal an exosome-mediated piRNA regulatory mechanism that synergistically amplifies VEGFC/VEGFR3 signaling to drive LN metastasis in BC, highlighting piR-hsa-28212 as a potential therapeutic target. Trial Registration: KYLL-2022-338.
Journal
|
FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C) • TBX1 (T-Box Transcription Factor 1) • METTL3 (Methyltransferase Like 3)
|
dactinomycin
6d
HIF1-driven TDP-43 stabilizes TRIP6 mRNA to drive angiogenesis and colorectal cancer progression under hypoxia. (PubMed, Transl Oncol)
Mechanistic studies, including chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), luciferase reporter, and actinomycin D assay, were conducted to elucidate HIF1-mediated transcriptional regulation of TARDBP and TDP-43-dependent stabilization of thyroid receptor-interacting protein 6 (TRIP6) mRNA...In vivo, TARDBP depletion inhibited tumor growth and downregulated metastasis-related factors in xenograft models. In conclusion, the HIF1-TARDBP-TRIP6 axis promotes CRC malignancy under hypoxia by integrating transcriptional activation and post-transcriptional mRNA stabilization, offering potential therapeutic targets for advanced CRC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • TARDBP (TAR DNA Binding Protein)
|
dactinomycin
7d
New trial
10d
Thermosensitive Gel Nasal Spray With Stem Cell Exosomes, Mupirocin, and DNase I for Chronic Sinusitis (clinicaltrials.gov)
P1, N=108, Not yet recruiting, The First Affiliated Hospital of Xinxiang Medical College
New P1 trial
10d
Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges. (PubMed, Front Surg)
She was managed according to the Chinese Children Cancer Group (CCCG)-WT-2019 protocol, receiving neoadjuvant VAD (vincristine, actinomycin D, and doxorubicin) chemotherapy, followed by staged bilateral nephron-sparing surgery. This highlights the limitations of current histology- and stage-based approaches for specific molecular subtypes. Current evidence supports more aggressive surgical intervention for high-risk cases, but it is essential to balance the need for renal function preservation with the goal of achieving oncological control.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
doxorubicin hydrochloride • vincristine • dactinomycin
10d
Integrated transcriptomics, network pharmacology and clinical expression validation reveal the prognostic significance of PANoptosis-related genes in cordycepin-treated lung adenocarcinoma. (PubMed, Discov Oncol)
Our results suggested that 8 biomarkers including SLC2A1, SMS, CCNA2, CDC25C, RNASE1, NR3C2, CAT, and ADA were associated with PANoptosis in LUAD. These findings may provide supportive evidence for the prognosis prediction and treatment of LUAD. However, the involvement of these genes in PANoptosis is currently only a hypothesis based on bioinformatics analysis and requires further experimental validation in the future.
Journal
|
CD4 (CD4 Molecule) • CCNA2 (Cyclin A2) • CDC25C (Cell Division Cycle 25C) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • RNASE1 (Ribonuclease A Family Member 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
cordycepin (OVI-123)
14d
Mechanism of METTL3 promoting rituximab resistance via β-catenin/MYC axis in double-expressor diffuse large B cell lymphoma. (PubMed, Pathol Res Pract)
METTL3 may drive DE-DLBCL cell cycle progression and RTX resistance by activating MYC and BCL2 transcription via YTHDF2-mediated m6A modification of β-catenin, revealing a novel mechanism of indirect transcriptional regulation in lymphoma and a potential therapeutic target.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • METTL3 (Methyltransferase Like 3) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
Rituxan (rituximab) • dactinomycin
14d
TRIM71 suppresses cervical cancer progression by inhibiting Nectin4-mediated Wnt/β-catenin signaling. (PubMed, Biol Direct)
TRIM71 may function as a tumor suppressor in CC by regulating Nectin4 expression and influencing Wnt/β-catenin signaling, EMT, tumor progression, and angiogenesis.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • TRIM7 (Tripartite Motif Containing 7)
|
dactinomycin
14d
Tumor-Associated Neutrophils Secrete AGR2 to Promote Colorectal Cancer Progression by Stabilizing ALYREF to Boost Snail m5C Modification. (PubMed, FASEB J)
The m5C modification level and stability of Snail mRNA were determined by MeRIP and actinomycin D assays...In vivo, AGR2 overexpression promoted tumor growth and EMT through neutrophil-dependent activation of the ALYREF-Snail axis. TAN-secreted AGR2 enhances ALYREF stability, thereby promoting m5C-dependent Snail mRNA stabilization and sustaining EMT and CRC progression.
Journal
|
AGR2 (Anterior gradient 2) • ALYREF (Aly/REF Export Factor) • CEACAM8 (CEA Cell Adhesion Molecule 8)
|
dactinomycin
15d
BADMC: Bacterial Decolonization Within Dyads (clinicaltrials.gov)
P=N/A, N=1, Completed, Duke University | Recruiting --> Completed | N=20 --> 1
Trial completion • Enrollment change
15d
Mechanism study of RUNX1/NSUN2 upregulating fatty acid-binding protein 5 through 5-methylcytosine methylation to mediate lipid metabolic reprogramming to promote immunotherapy resistance in non-small cell lung cancer. (PubMed, Respir Res)
RUNX1 alters m⁵C methylation levels by regulating NSUN2 transcription to promote FABP5-mediated lipid metabolic reprogramming, which in turn enhances PD-L1 expression and consequently induces immune resistance in NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • RUNX1 (RUNX Family Transcription Factor 1) • FABP5 (Fatty Acid Binding Protein 5) • NSUN2 (NOP2/Sun RNA Methyltransferase 2)
|
PD-L1 expression
|
dactinomycin